1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

New market study, "Novartis AG: PharmaVitae Profile", has been published

New Pharmaceuticals market report from Datamonitor: "Novartis AG: PharmaVitae Profile"

 
PRLog - May 16, 2011 - Introduction

This analysis examines the historical and forecast performance for Novartis in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits

* Gain insight into Novartis's strategic outlook across the next 6 years.* Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source.

Highlights

Strategic insight into the prospects for Novartis over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered

* Benchmark Novartis's performance against key rivals in the prescription pharmaceutical sector* Assess how Novartis is forecast to deliver the strongest prescription pharmaceutical sales growth of any Big Pharma company over the period 2009-15.* Analyse Novartis's 'focused diversification' strategy based on its presence in the branded, generic, vaccine, eyecare and consumer health segments.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/158609_novartis_ag_pharmavitae...
------------------------------------------------------------


Partial Table of Contents:

TABLE OF CONTENTS
ABOUT DATAMONITOR HEALTHCARE
About the PharmaVitae team
Chapter 1 About this profile
PharmaVitae Explorer database
Chapter structure
Data sourcing
Chapter 2 Executive summary
Key findings
Prescription pharmaceutical sales and growth rate performance, 2003-15
Financial performance, 2003-15
Novartis: PharmaVitae forecasts at a glance
Strategic insight
SWOT analysis
Chapter 3 Quarterly update
Latest quarterly sales
Latest quarterly financial analysis
Latest comment
Latest prescription pharma product news
Latest corporate news
Chapter 4 Company introduction
Key findings
Background
Key corporate developments
M&A history
Chapter 5 Company sales
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003-15
Product analysis
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Molecule type analysis
Externalization analysis
Chapter 6 Company financials
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003-09
Operating costs and profit analysis
Chapter 7 Key products
Overview
Chapter 8 Appendix
References
Abbreviations
Exchange rates
About Datamonitor
Datamonitor consulting
Disclaimer

TABLE OF TABLES
Table 1: Novartis - PharmaVitae forecasts at a glance
Table 2: Novartis quarterly sales ($m), Q309-Q310
Table 3: Novartis quarterly financials ($m), Q309-Q310
Table 4: Novartis product portfolio overview ($m), 2003-09
Table 5: Novartis product portfolio overview ($m), 2009-15
Table 6: Novartis prescription pharmaceutical sales by therapy area ($m), 2009-15
Table 7: Novartis prescription pharmaceutical sales by geographic region ($m), 2009-15
Table 8: Novartis launch portfolio overview ($m), 2009-15
Table 9: Novartis core portfolio overview ($m), 2009-15
Table 10: Novartis expiry portfolio overview ($m), 2009-15
Table 11: Novartis (Sandoz) generics portfolio overview ($m), 2009-15
Table 12: Novartis prescription pharmaceutical sales by molecule type ($m), 2009-15
Table 13: Novartis prescription pharmaceutical sales by source ($m), 2009-15
Table 14: Total Novartis sales by business unit ($m), 2003-09
Table 15: Novartis operating revenue/cost analysis ($m), 2003-09
Table 16: Novartis operating cost ratio analysis (% of total revenues), 2003-09
Table 17: Novartis operating cost ratio analysis (% of total revenues), 2009-15
Table 18: Novartis operating revenue/cost analysis ($m), 2009-15
Table 19: Novartis Key products overview
Table 20: Glivec/Gleevec: overview
Table 21: Glivec/Gleevec: sales forecast ($m), 2009-15
Table 22: Gilenia: overview
Table 23: Gilenia: sales forecast ($m), 2009-15
Table 24: QMF149: overview
Table 25: QMF149: sales forecast ($m), 2009-15
Table 26: QVA149: overview
Table 27: QVA149: sales forecast ($m), 2009-15
Table 28: Tasigna: overview
Table 29: Tasigna: sales forecast ($m), 2009-15
Table 30: Diovan: overview
Table 31: Diovan: sales forecast ($m), 2009-15
Table 32: Co-Diovan: overview
Table 33: Co-Diovan: sales forecast ($m), 2009-15
Table 34: Zometa: overview
Table 35: Zometa: sales forecast ($m), 2009-15
Table 36: Femara: overview
Table 37: Femara: sales forecast ($m), 2009-15
Table 38: Sandostatin: overview
Table 39: Sandostatin: sales forecast ($m), 2009-15
Table 40: Exchange rates, 2010

TABLE OF FIGURES
Figure 1: The PharmaVitae Explorer
Figure 2: Novartis prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003-15
Figure 3: Novartis's financial performance ($m), 2003-15
Figure 4: Novartis prescription pharmaceutical sales growth by business area ($m), 2009-15
Figure 5: Novartis prescription pharmaceutical sales growth by business area (branded portfolio segmented) ($m), 2009-15
Figure 6: Sandoz corporate structure demonstrating diverse growth opportunities
Figure 7: Sandoz M&A driven geographic expansion ($m), 2003-15
Figure 8: Synergies between Alcon and Novartis
Figure 9: Novartis SWOT analysis
Figure 10: Sandoz M&A history, 2001-09

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=1586...

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment.  View more research from Datamonitor at http://www.fastmr.com/catalog/publishers.aspx?pubid=1002

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

--- End ---

Click to Share

Contact Email:
***@fastmr.com Email Verified
Source:Fast Market Research
Phone:1.800.844.8156
Zip:01267
State/Province:Massachusetts - United States
Industry:Medical, Research, Biotech
Tags:novartis, prescription, pharmaceutical, 2003-15, pharmavitae, 2003-09, molecule, therapy, sandoz, revenuecost
Shortcut:prlog.org/11491774
Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “

More...

Trending News...



  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
9K2K1K
Click to Share